Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Dementia specialists have pinpointed certain eating habits as potential early indicators of frontotemporal dementia (FTD). As ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

Protective cultures are beneficial lactic acid bacteria that can prevent the growth of unwanted bacteria. Buffered vinegar is ...

There's no question that AI systems have accomplished some impressive feats, mastering games, writing text, and generating ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

NORTH CHICAGO, IL, USA and HØRSHOLM, Denmark I March 3, 2025 I AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...

Scientists at VCU Massey Comprehensive Cancer Center have identified an innovative combination of treatment strategies that ...